Discover
DXCM
DexCom, Inc.
92.34
2 x 83.86
2 x 97.15
bid
ask
+
2.12
2.35%
2 @ 07:56 PM
92.23 -0.11 (0.12%)
| Ytd | 39.13% | |
| 1y | 14.54% |
89.20
day range
92.56
54.84
52 week range
92.34
| Open | 89.61 | Prev Close | 90.22 | Low | 89.20 | High | 92.56 | Mkt Cap | 34.85B |
| Vol | 3.48M | Avg Vol | 5.24M | EPS | 2.53 | P/E | 36.50 | Forward P/E | 29.55 |
| Beta | 1.41 | Short Ratio | 3.68 | Inst. Own | 106.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 77.63 | 200-d Avg | 69.32 | 1yr Est | 94.12 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-10-29 | 2026-09 | 0.66 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | 0.61 | 0.7 | 0.09 | 14.57% |
| 2026-04-30 | 2026-03 | 0.47 | 0.56 | 0.09 | 20.27% |
| 2026-02-12 | 2025-12 | 0.65 | 0.68 | 0.03 | 4.62% |
| 2025-10-30 | 2025-09 | 0.58 | 0.61 | 0.03 | 5.90% |
| 2025-07-30 | 2025-06 | 0.44 | 0.48 | 0.04 | 8.21% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-04 | Argus Research | Upgrade | Buy | Buy |
| 2026-08-03 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-07-31 | Citigroup | Upgrade | Buy | Buy |
| 2026-07-31 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-07-31 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-07-31 | JP Morgan | Upgrade | Neutral | Neutral |
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-27 | ALTMAN STEVEN R | Director | 69.23K | Stock Award(Grant) |
| 2026-08-13 | BROWN MICHAEL JON | Officer | 102.95K | Sale |
| 2026-06-03 | COLEMAN JON | Officer | 95.45K | Sale |
| 2026-05-27 | COLLINS RICHARD ALEXANDER | Director | 45.77K | Stock Award(Grant) |
| 2026-08-02 | FOLETTA MARK G | Director | 0.00 | Sale |
| 2026-03-05 | LEACH JACOB STEVEN | Chief Executive Officer | 469.11K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 38.24M | 3.53B | 10.13% |
| 2026-06-29 | Vanguard Capital Management LLC | 25.21M | 2.33B | 6.68% |
| 2026-06-29 | Vanguard Portfolio Management LLC | 19.66M | 1.82B | 5.21% |
| 2026-06-29 | State Street Corporation | 18.38M | 1.70B | 4.87% |
| 2026-06-29 | Invesco Ltd. | 15.29M | 1.41B | 4.05% |
| 2026-06-29 | BAILLIE GIFFORD & CO | 14.80M | 1.37B | 3.92% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 12.22M | 1.13B | 3.24% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 9.78M | 903.03M | 2.59% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 8.31M | 767.50M | 2.20% |
| 2026-06-29 | Invesco QQQ Trust, Series 1 | 8.19M | 756.36M | 2.17% |
| 2026-04-29 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 6.37M | 587.76M | 1.69% |
| 2026-06-29 | iShares Trust-iShares Core S&P 500 ETF | 5.33M | 492.23M | 1.41% |
Split
| Split | Date |
|---|---|
| 4 : 1 | 2022-06-13 |
| 4 : 1 | 2022-06-10 |